 Niacinamide
"Niacinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
| Descriptor ID |
D009536
|
| MeSH Number(s) |
D03.066.515.530 D03.383.725.547.530
|
| Concept/Terms |
Niacinamide- Niacinamide
- Vitamin PP
- Vitamin B 3
- B 3, Vitamin
- Vitamin B3
- B3, Vitamin
- 3-Pyridinecarboxamide
- 3 Pyridinecarboxamide
- Nicotinamide
Papulex- Papulex
- Pharmagenix Brand of Niacinamide
- Niacinamide Pharmagenix Brand
Nicotinsäureamid Jenapharm- Nicotinsäureamid Jenapharm
- Jenapharm, Nicotinsäureamid
- Jenapharm Brand of Niacinamide
- Niacinamide Jenapharm Brand
Nicobion- Nicobion
- Merck Brand of Niacinamide
- Niacinamide Merck Brand
- Astra Brand of Niacinamide
- Niacinamide Astra Brand
|
Below are MeSH descriptors whose meaning is more general than "Niacinamide".
Below are MeSH descriptors whose meaning is more specific than "Niacinamide".
This graph shows the total number of publications written about "Niacinamide" by people in this website by year, and whether "Niacinamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1985 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 5 | 5 | | 2007 | 0 | 3 | 3 | | 2008 | 0 | 4 | 4 | | 2009 | 0 | 7 | 7 | | 2010 | 0 | 6 | 6 | | 2011 | 0 | 6 | 6 | | 2012 | 3 | 1 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 4 | 1 | 5 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 2 | 3 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Kavanagh ON, Wang C, Walker GM, Sun CC. Modulation of the powder properties of lamotrigine by crystal forms. Int J Pharm. 2021 Feb 15; 595:120274.
-
Srivastava A, Cai X, Lee J, Li W, Larive B, Kendrick C, Gassman JJ, Middleton JP, Carr J, Raphael KL, Cheung AK, Raj DS, Chonchol MB, Fried LF, Block GA, Sprague SM, Wolf M, Ix JH, Prasad PV, Isakova T. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin J Am Soc Nephrol. 2020 06 08; 15(6):776-783.
-
Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol. 2019 06; 30(6):1096-1108.
-
Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženovic I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
-
Yamashita H, Sun CC. Expedited Tablet Formulation Development of a Highly Soluble Carbamazepine Cocrystal Enabled by Precipitation Inhibition in Diffusion Layer. Pharm Res. 2019 Apr 23; 36(6):90.
-
Yu X, Liu F, Zeng L, He F, Zhang R, Yan S, Zeng Z, Shu Y, Zhao C, Wu X, Lei J, Zhang W, Yang C, Wu K, Wu Y, An L, Huang S, Ji X, Gong C, Yuan C, Zhang L, Feng Y, Huang B, Liu W, Zhang B, Dai Z, Wang X, Liu B, Haydon RC, Luu HH, Gan H, He TC, Chen L. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells. Cell Physiol Biochem. 2018; 47(3):957-971.
-
Caiola E, Frapolli R, Tomanelli M, Valerio R, Iezzi A, Garassino MC, Broggini M, Marabese M. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948.
-
Pham MN, Apolo AB, De Santis M, Galsky MD, Leibovich BC, Pisters LL, Siefker-Radtke AO, Sonpavde G, Steinberg GD, Sternberg CN, Tagawa ST, Weizer AZ, Woods ME, Milowsky MI. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World J Urol. 2017 Mar; 35(3):367-378.
-
Ai T, Wilson DJ, More SS, Xie J, Chen L. 5-((3-Amidobenzyl)oxy)nicotinamides as Sirtuin 2 Inhibitors. J Med Chem. 2016 Apr 14; 59(7):2928-41.
-
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|